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Abstract
Background: M2 proton channel of H1N1 influenza A virus is the target protein of anti-flu drugs amantadine and rimantadine.
However, the two once powerful adamantane-based drugs lost their 90% bioactivity because of mutations of virus in recent
twenty years. TheNMR structure of the M2 channelprotein determined by Schnelland Chou (Nature, 2008, 451, 591–595) may
help people to solve the drug-resistant problem and develop more powerful new drugs against H1N1 influenza virus.
Methodology: Docking calculation is performed to build the complex structure between receptor M2 proton channel and
ligands, including existing drugs amantadine and rimantadine, and two newly designed inhibitors. The computer-aided
drug design methods are used to calculate the binding free energies, with the computational biology techniques to analyze
the interactions between M2 proton channel and adamantine-based inhibitors.
Conclusions: 1) The NMR structure of M2 proton channel provides a reliable structural basis for rational drug design against
influenza virus. 2) The channel gating mechanism and the inhibiting mechanism of M2 proton channel, revealed by the NMR
structure of M2 proton channel, provides the new ideas for channel inhibitor design. 3) The newly designed adamantane-
based inhibitors based on the modeled structure of H1N1-M2 proton channel have two pharmacophore groups, which act
like a ‘‘barrel hoop’’, holding two adjacent helices of the H1N1-M2 tetramer through the two pharmacophore groups
outside the channel. 4) The inhibitors with such binding mechanism may overcome the drug resistance problem of
influenza A virus to the adamantane-based drugs.
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Introduction
Recently, the outbreak of H1N1 influenza A virus is a pandemic
of a new strain of influenza virus [1] identified in April 2009,
commonly referred to as ‘‘swine flu’’. Within only four months, the
pandemic has caused many deaths from the first detected country
Mexico to almost all countries of the world (http://www.who.int/
csr/disease/swineflu/). The H1N1 influenza virus is quite familiar
to us because it had caused the 1918–1919 Spain pandemic that
had infected 5% of the world population and resulted in 20–50
million deaths worldwide [1]. In July 2009 the WHO (World
Health Organization) enhanced the warning to phase 6, meaning
that the spread of H1N1 influenza virus has become a serious
global pandemic. It was anticipated that a stronger outbreak might
occur in the coming winter. The even worse news is that cases
were reported that several strains of H1N1 influenza A viruses
were resistant to oseltamivir (Tamiflu).
Although an influenza virus only possesses eight genes (far less
than the estimated 25,000 that a human being has), its simplicity
has not stopped it from wreaking havoc on human beings for
centuries. ‘‘The only thing predictable about influenza is its
unpredictability’’ [2]. Influenza A virus has the ability to undergo
changes by the mechanisms of antigenic drift and shift, resulting in
new evolving virus strains, which may be extremely toxic and
drug-resistant [3–5]. Given that influenza shifts may occur every
20–30 years, the danger of future influenza A pandemics
highlights the need to develop more effective drugs. The threat
of an impending influenza pandemic, possibly through the
mutations of the present avian strain H5N1 or swine strain
H1N1, has triggered a global effort to develop more effective
antivirus drugs. However, during the past several decades many
efforts in developing anti influenza drugs have almost been futile
due to the rapid mutations of the influenza virus, resulting in the
persistent resistance to the existing drugs.
The M2 protein [6–9] from influenza A virus is a pH-sensitive
proton channel that mediates acidification of the interior of viral
particles entrapped and replication in endosomes [10]. Since the
M2 protein was found, it has been the main target for finding
drugs against influenza A virus. The adamantane-based drugs,
amantadine and rimantadine [11–13], which target the M2
channel, had been used for many years as the first-choice antiviral
drugs against community outbreaks of influenza A viruses.
However, the once powerful drugs lost their effectivity quickly
due to mutations and evolutions of influenza A viruses. Recent
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adamantane-based drugs in humans, birds and pigs has reached
more than 90% [3,4].
To solve the drug-resistance problem, a reliable molecular
structure of M2 proton channel is absolutely necessary [14,15].
Very recently, using high-resolution nuclear magnetic resonance
(NMR) spectroscopy, Schnell and Chou [16] for the first time
successfully determined the solution structure of M2 proton
channel. They reported an unexpected mechanism of its inhibition
by the flu-fighting adamantane drug family. According to the
novel mechanism, rimantadine binds at four equivalent sites near
the ‘‘tryptophan gate’’ on the lipid-facing side of the channel and
stabilizes the closed conformation of the pore. This is completely
different from the traditional view but more reasonable in the
sense of energetics [17–19].
The new discovery of M2 proton channel structure has brought
us the light, by which the drug-resistance problem may be solved,
and more powerful adamantine-based drugs may be developed.
This is because if we can understand how the drug blocks the
channel and how mutations evade the effect of the drug, we can
come up with better approaches to block it [20].
Based on such a rationale as well as the high-resolution NMR
structure of M2 proton channel [16], the present study was
initiated in an attempt to solve the drug resistant problem and to
design more effective adamantine-based drugs by conducting
molecular modeling and docking studies.
Materials and Methods
Until September 4, 2009, a total of 48 amino acid sequences of
H1N1-M2 proton channel proteins are deposited in the website
NCBI (www.ncbi.nlm.nih.gov). However, no experimental 3D
(three-dimensional) structure of H1N1-M2 protein is reported so
far. To develop its 3D structure, the H1N1-M2 protein sequence
with the NCBI code of GQ385303 (www.ncbi.nlm.nih.gov) is
used in this study. The sequence is isolated in Toronto from a
H1N1 virus strain in July 2009. To build the three dimensional
structure of GQ385303, the high-resolution NMR structure of
M2 proton channel [16] with the PDB code of 2RLF (www.rcsb.
org/pdb) was adopted as a template, which was determined for
the M2 channel isolated from the Udorn strain of human
influenza virus.
The sequence alignment is performed between the targeted
protein (GQ385303) and the template (2RLF). The result of
alignment is shown in Fig. 1, where the characters highlighted in
red indicate the three functional residues (pH sensor His37,
channel gate Trp41, and channel lock Asp44) [16–18,21,22] of the
M2 channel, which are highly conserved in the M2 proteins.
Those residues with the light-blue frame are the possible binding
sites (Thr43, Asp44, and Arg45) of the inhibitors; while those with
the green frame are different between the two sequences.
Thus, using the structural bioinformatics tools [23], the 3D
structure of the H1N1-M2 (GQ385383) channel was developed
by following the same procedures as elaborated in references [24–
26]. The computed 3D structure of H1N1-M2 channel
(GQ385383) is shown in Fig. 2A. Subsequently, the Auto Dock
program [27] with the MMFF94 force field and atomic partial
charges [28] was utilized to dock the ligands to the H1N1-M2
channel. The starting point of the docking calculations was the
position at which the drug rimantadine is located in the NMR
structure of 2RLF [16]. A cubic box with side length of 30 A ˚
surrounding the ligand was used for the docking calculations. A
total of 25 docking conformations with the lowest binding
energies were recorded.
Figure 1. The sequence alignments between the M2 protein isolated from H1N1 influenza A virus (NCBI code: GQ385383) and the
M2 channel isolated from the Udorn strain of human influenza virus. The latter 3D structure has been determined by NMR [16] with PDB
code of 2RLF, and can be used to serve as a template to model the former. The GQ385383 is a complete M2 sequence consisting of 97 residues, while
2RLF only contains a segment of 43 structure-defined residues (18–60). The red codes highlight the functional residues: pH sensor His37, channel
gate Trp41, and channel lock Asp44. Those residues, which are different between the two M2 sequences, are framed by a box drawn in green line,
while those framed with a box drawn in light-blue line indicate the possible binding sites (Thr43, Asp44, and Arg45) of inhibitors. The functional
residue Asp44 is the first binding site, and the Arg45 or Thr43 is the possible second binding site. Thr43 is a natural mutation Leu43Thr in the H1N1-
M2 proton channel.
doi:10.1371/journal.pone.0009388.g001
M2 Channel Inhibitor Design
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9388Results
Before the 3D NMR structure of M2 protein [16] was
published, it was traditionally thought that the adamantane-based
inhibitors were bound inside the channel and hence physically
blocking the pore of channel [6]. With the novel allosteric
inhibition mechanism revealed by the NMR structure [16], we can
conduct the structure-based inhibitor design and find effective
drugs against the H1N1-M2 channel in a completely different
strategy [19,29], as illustrated below.
Computed Structure of H1N1 M2 Proton Channel
By following the procedures as described in the Materials and
Methods section, the 3D structure of H1N1-M2 (GQ385383) was
developed as shown in Fig. 2A, where for facilitating comparison
the template structure is also given in a superposition manner with
the targeted structure. The structural data can be provided by
authors upon inquire. As we can see from the figure, the
backbones of the two structures are almost the same as expected
because the sequences of the two proteins are highly homologous.
The three functional residues (His37, Trp41, and Asp44) of the
M2 channel are rendered in ball-and-stick drawing with the
chemical element color. They are located at the middle of the
channel. The different residues between the two channel structures
are shown in green for 2RLF and blue for GQ385383. Most
mutated residues in H1N1-M2 protein are at the top and bottom
of the channel, and they have little effects on the functional
residues (His37, Trp41, and Asp44). However, one mutation,
namely Leu43Thr, is found around the active region: the non
polar residue Leu43 of 2RLF is replaced by the polar residue
Thr43 in the H1N1-M2 protein. A close-up view from the bottom
of the M2 channel is given in Fig. 2B to show the position and
orientation of the three functional residues and the position of
ligand rimantadine. The three functional residues are rendered in
green for pH sensor His37, blue for channel gate Trp41, and
chemical element color for channel lock Asp44, respectively.
Ligand rimantadine binds at four equivalent sites near the channel
lock Asp44 on the lipid-facing side of the channel. The Asp44
residue is not only the channel lock, but also the proton exit of the
M2 channel. Therefore, drug binding at this position not only can
hold the channel in the closed conformation but also can simply
block the proton exits. [22].
Illustrated in Fig. 2C is the gating and inhibiting mechanism of
the M2 proton channel [16–18,22]. The channel lock Asp44 holds
Figure 2. The computational three-dimensional structure of 2009-H1N1 M2 proton channel (NCBI code: GQ385303) and the
template 2RLF with ligand rimantadine. (A) Superposition of the homology model of 2009-H1N1 M2 proton channel with its template, the NMR
structure with the PDB code of 2RLF [16]. The two M2 proteins are highly homologous, and no differences are found on their backbones. The three
functional residues of the M2 channel are rendered in ball-and-stick drawing with chemical element color; they are located at the middle of the
channel. The different residues between two M2 proteins are show in green for 2RLF and blue for GQ385383. (B) A close-up view from the bottom of
the M2 channel. The three functional residues are rendered in green for pH sensor His37, blue for channel gate Trp41, and chemical element color for
channel lock Asp44. The ligand rimantadine binds at four equivalent sites near the channel lock Asp44 on the lipid-facing side of the channel and
stabilizes the closed conformation of the pore. (C) The complex structure between the inhibitor rimantadine and the receptor M2 proton channel.
The channel lock Asp44 holds the channel gate Trp41 through a hydrogen bond keeping it in the closed conformation. The ligand rimantadine forms
two hydrogen bonds (green dotted lines) with the Asp44 of M2 proton channel.
doi:10.1371/journal.pone.0009388.g002
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the closed conformation in the middle or higher pH (,7.5)
condition. But in the lower pH environment, the pH sensor His37
and the indole amine of Trp41 are protonated, so as to weaken the
hydrogen bond between Trp41 and Asp44, making it easily
broken by the repulsive interaction between the positively charged
His37 residues of two adjacent helix chains. After rimantadine
binds at the Asp44 through two hydrogen bonds between amino
group of rimantadine and carboxyl group of Asp44, the pKa value
of Asp44 is lowered by the two hydrogen bonds [30,31].
Therefore, in the lower pH environment, it becomes difficult for
Asp44 to be protonated. That is why in the acidic condition the
ligand rimantadine can help Asp44 to keep the channel in the
closed conformation.
Inhibitors with Two Pharmacophore Groups
Almost all existing M2 channel inhibitors have only one
pharmacophore group, and in most cases it is an amino group
[19]. The structures of several adamantane-based drugs are shown
in Fig. 3, where the inhibitors A1 and A2 are commercially
available drugs amantadine and rimantadine, respectively, in
which the pharmacophore substitutes are at the position 3 of
adamantine [13,32,33]. Actually, the pharmacophore substitutes
also can be put on the position 2 of adamantine [11,12,19], and in
many cases the substitutes on position 2 can give better results than
on the position 3 [19].
The M2 channel is a tetramer consisting of four identical
helices. As shown in Fig. 4A, the adamantane-based inhibitor
with one pharmacophore group can only bind on one helix of the
tetrameric M2 channel. If an additional pharmacophore group is
added into the adamantane-based inhibitor, it will be able to bind
at two sites of two neighboring helices. Thus, the inhibitor will be
able to hold the M2 channel in the closed conformation with a
more effective way, just like a hoop in fastening a barrel, as shown
by Fig. 4B. Actually only one such inhibitor molecule would be
sufficient to block the M2 channel because the hoop-like inhibitor
can block half of the channel and stop the conductance of proton
(H3O
+) flow.
Structure-Based Inhibitor Design for M2 Protein
The discussions for the adamantane-based inhibitors with more
than one pharmacophore groups can be found in references
Figure 3. Summary of the existing adamantane-based drugs and newly designed inhibitors with two pharmacophore groups. A1
and A2 are the commercially available drugs amantadine and rimantadine. A3 was reported in ref [13]. A4 and A5 are inhibitors with two
pharmacophore groups designed in this study.
doi:10.1371/journal.pone.0009388.g003
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available, this kind of design was lack of a footing since we did not
know the binding site and the interaction mechanism of the second
pharmacophore. The inhibitor A3 in Fig. 3 has two amino groups
and possesses the bioactivity slightly higher than that of
rimantadine [12,13]. However, based on our docking studies,
the A3 inhibitor could not effectively bind at the two neighboring
helices. The inhibitor with two pharmacophore groups needs two
binding sites on the M2 channel. The first binding site is
unchangeably the carboxyl group of the Asp44, while the second
binding site could be either the amino group of Arg45 or the
hydroxyl group of Thr43 of the neighboring helix. These two
residues are the closest residues to the first binding site Asp44.
With two pharmacophore groups, the inhibitors A4 and A5 in
Fig. 3 were designed based on the structure of H1N1-M2 proton
channel. On the subsite of inhibitor A4 corresponding to the
position 3 of adamantine, there is an amino group and a hydroxyl
group. Docking calculation gives an illustration for the interactions
between the designed inhibitor A4 and the M2 proton channel.
The amino group of inhibitor A4 binds at the 1-Asp44 of Chain-1
through two hydrogen bonds, while the second pharmacophore
hydroxyl group forms two hydrogen bonds with the amino group
of 2-Arg45 of Chain-2. The detailed interactions between M2
channel and the ligand A4 are shown in Fig. 5. It is through the
two binding sites that the inhibitor A4 holds the Chain-1 tightly
with its adjacent Chain-2 of the tetrameric M2 proton channel.
Actually, the inhibitor A4 was firstly synthesized by Clariana et al.
in 2000 [34] not as an anti flu drug, but as a reagent for studying
peptide–receptor interactions. As for inhibitor A4, no bioactivity
data to M2 proton channel was reported.
The designed inhibitor A5 has two pharmacophore groups: a
hydroxyl group on position 2 and an amino group on position 3 of
adamantane. Illustrated in Fig. 6 is a close view of the interactions
between the designed inhibitor A5 and the M2 proton channel.
The amino group of inhibitor A5 binds at the carboxyl group of 1-
Asp44 of Chain-1 through two hydrogen bonds, while the second
pharmacophore hydroxyl group forms two hydrogen bonds with
the amino group of 2-Arg45 of Chain-2. Therefore, it is in the
same way as inhibitor A4 that the inhibitor A5 holds the Chain 1
tightly with its adjacent Chain 2 of the tetrameric M2 proton
channel.
Energetic Analysis for M2 Channel-Inhibitor Interactions
During the molecular docking of the inhibitors to the tetrameric
M2 proton channel, a total of 25 conformations with the strongest
binding energies were recorded for each of the five inhibitors in
Fig. 3, where the most favorable binding energy for each of the
five inhibitors are also given. It can be seen from the Fig. 3 that
DEA1,DEA2 ,DEA3,,DEA5,DEA4, indicating that the binding
free energies of A4 and A5 are much stronger than those of A1
Figure 4. The binding models between M2 proton channel and adamantane-based inhibitors with one and two pharmacophore
groups. (A) The adamantane-based inhibitors with one pharmacophore group can bind on only one helix of the tetrameric M2 channel. (B) With an
additional pharmacophore group added into the adamantane-based inhibitors, the inhibitors can bind at the two sites of two neighboring helices of
the M2 channel, and hence can hold the M2 channel in closed conformation more effectively, just like a barrel hoop. Actually only one such inhibitor
is sufficient to block the M2 channel because it can block half of the channel and stop the conductance of proton (H3O
+) flow effectively.
doi:10.1371/journal.pone.0009388.g004
Figure 5. Illustration to show the interactions between the
designed inhibitor A4 (Ad—3—aminoethanol) and the M2
proton channel. The designed adamantane-based inhibitor A4 has
two pharmacophore groups. The amino group binds at the 1-Asp44 of
Chain-1 through two hydrogen bonds (green dotted lines), while the
second pharmacophore hydroxyl group forms two hydrogen bonds
with the 2-Arg45 of Chain-2. It is through the two binding sites that the
inhibitor A4 holds the Chain 1 tightly with its adjacent Chain 2 of the
tetrameric M2 proton channel.
doi:10.1371/journal.pone.0009388.g005
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namely the hydroxyl group, which forms two additional hydrogen
bonds with the receptor. Although A3 inhibitor also possesses two
amino groups and the second amino group can form hydrogen
bonds with the amino group of Arg45, the hydrogen bonds
between the two amino groups are easily broken in acidic
condition.
Discussion
The NMR structure of M2 proton channel [16] provides a
reliable structural basis for rational drug design against influenza
virus. The channel gating mechanism and the inhibiting
mechanism of M2 proton channel, revealed by the NMR structure
of M2 proton channel, stimulate the new idea and strategy for
channel inhibitor design. The two inhibitors (A4 and A5) of M2
proton channel, designed in this study, are hopefully the potential
drugs for the 2009-H1N1 swine flu.
The adamantane-based drugs (amantadine and rimantadine)
are not like the ordinary drug molecules from the viewpoint of
Lipinski’s ‘‘the rule of five’’ [35], a rule of thumb to evaluate
druglikeness, or to determine if a chemical compound with a
certain pharmacological or biological activity has properties that
would make it a likely orally active drug in humans. This is
because amantadine and rimantadine possesses very few pharma-
cophore groups and very few hydrogen-bond-forming elements.
Rimantadine can hold one of the four helices in the tetrameric M2
proton channel by one, and only one, pharmacophore amino
group. An additional pharmacophore group is needed to hold the
adjacent helix of the tetrameric channel so as to strengthen its
closed conformation for blocking the proton conductance. The
high-resolution NMR structure of the M2 proton channel [16] and
the gating and inhibiting mechanism revealed therefrom has made
it possible to rationally design new and more powerful drugs
against influenza viruses. It is the second pharmacophore group in
the inhibitors A4 and A5 that might significantly enhance their
ability in inhibiting the M2 channel in comparison with
amantadine and rimantadine.
The M2 proton channel is a membrane protein; while the
adamantane-based inhibitors are detergent-like compounds with a
hydrophilic head and a hydrophobic body, possessing the ability to
penetrate the bilayer lipid membrane. Although the second
additional hydrophilic pharmacophore group of A4 and A5
inhibitors can enhance their inhibition ability to the M2 proton
channel, it might lower their ability in penetrating membrane.
Therefore, a series of follow-up experiments are needed along this
direction to find an optimal inhibitor by taking into account these
two aspects.
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